Table 1: Summary of characteristics in 25 patients with invasive giant prolactinomas treated with dopamine agonists.

Case number GenderAge PRL ng/mL Three dimensions × × (mm)Followup (month)Treatment method Range of tumor invasionMaximum treatment doseMaintenance dose (mg)
Before TxAfter TxBefore TxAfter Tx% changePre-TxPost-Txdose (mg)duration (month)

1M403154.8Normal40 × 34 × 300100143S + BRC + RTR-CS, TV07.5122.5
2M26>4000Normal55 × 52 × 3816 × 15 × 1197.6192BRCB-CS, Cl, TVL-CS7.5602.5
3M291680878.970 × 68 × 5030 × 14 × 25/34 × 12 × 2092.2144BRCB-CS, Cl, SS, NC, TVB-CS15105
4M24>200Normal40 × 57 × 350100123BRCB-CS07.5602.5
5F47>200Normal40 × 40 × 170100131BRCL-CS07.5241.25
6M34>200Normal42 × 48 × 300100119S + BRCB-CS, SS, TV07.51197.5
7M343821Normal31 × 42 × 280100112S + BRCB-CS07.5123.75
8M233814Normal50 × 21 × 23010092S + BRCB-CS05121.25
9F5212711.8Normal46 × 33 × 360100105S + BRCR-CS051055
10F26>20038352 × 50 × 38≈099.9173BRC + GKR-CS, Cl, IPC, R-TL012.596
11F22110031742 × 20 × 200100141BRC + GKR-CS, TV01560
12F24>200Normal38 × 42 × 350100122BRC + SR-CS020242.5
13M481431.4Normal60 × 54 × 500100142BRCB-CS, TV, R-TL07.5240
14F22>200Normal67 × 45 × 4032 × 12 × 1695136BRC + RTL-CS, SS, Cl, TV, LVTV, IS7.5125
15M49>8000Normal65 × 55 × 450100165BRC + RTL-CS, SS, Cl, TV, L-TL07.5302.5
16M49>4000Normal63 × 40 × 450100147BRCB-CS, SS, Cl, TV07.5352.5
17M33>6000Normal58 × 49 × 51≈099.9162S + BRC + RTB-CS, SS, Cl, TV, NC07.5552.5
18M50>200Normal50 × 30 × 3012 × 18 × 896130S + BRCL-CS, TVL-CS51305
19F37>8000Normal73 × 60 × 540100153BRC + RTR-CS, SS, Cl, TV, IPC, R-TL07.570
20M1596014172 × 48 × 5240 × 25 × 2088.9133S + BRCB-CS, SS, Cl, TV, IPC, L-TLL-CS159010
21M44>200Normal46 × 48 × 340100119BRC + RTB-CS, TV, FL05120
22M46>500Normal62 × 51 × 50010090S + BRCR-CS, R-FL, R-TL017.560
23M47>200Normal60 × 40 × 440100138BRCB-CS, SS, Cl07.5252.5
24M31>600020760 × 42 × 38≈099.9135BRCL-CS, TV, L-TL07.51357.5
25M40>40007655 × 52 × 3014 × 15 × 2095140BRCB-CS, SS, ClR-CS7.537.5

Mean35.798.6135.58.948.5

SEM2.20.64.70.88.3

Most recent finding; M: male, F: f, Tx: treatment, S + BRC + RT: surgery + bromocriptine + radiotherapy, GK: gamma knife, R: right, L: left, B: bilateral, CS: cavernous sinus, SS: sphenoidal sinus, Cl: clivus, TV: third ventricule, IPC: interpeduncular cistern, FL: frontal lobe, TL: temporal lobe, NC: nose cavity, LV: lateral ventricule, and IS: intrasellar.
Values represent those for tumor areas , , and , respectively.
This patient suffered from severe cognitive decline due to cerebral atrophy and cerebral infarction and died on March 13, 2015.
This patient changed to accept cabergoline treatment (2 mg per week) due to BRC resistance and had normal PRL level.
Patient withdrew BRC treatment for 35 months. Hyperprolactinemia and tumor recurrence was observed and BRC therapy was restarted.
Those two patients had self-discontinued therapy without evidence of tumor recurrence.